- Tytuł:
- 123P IMpower010: Exploratory overall survival (OS) with adjuvant atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression
- Autorzy:
- Źródło:
- In Immuno-Oncology and Technology December 2022 16 Supplement 1
Czasopismo naukowe